|
Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology,
DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.
DehydraTECH is covered by 23 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.
Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.
Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.
The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce
cannabinoid beverages, edibles and oral products.
DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.
Investment Considerations
- Lexaria Bioscience Corp. has disruptive proprietary technology protected by a broad international patent portfolio.
- The company has been issued 23 patents in the U.S., European Union and other countries, with more than 50 patents pending around the world.
- Lexaria’s DehydraTECH technology has a vast worldwide, multi-billion-dollar total addressable market, including multiple rapid-growth segments like cannabinoid and noncombustible nicotine delivery.
- The company has licensed its fat-soluble active molecule delivery technology to multiple established companies for use in their products.
- Lexaria completed an uplisting to Nasdaq Capital Markets and an $11 million financing in January 2021.
Recent Coverage
Lexaria Bioscience Corp. (NASDAQ: LEXX) Technology Continues to Showcase Ability to Improve Effectiveness of Existing Drug Brands
April 1, 2022 9:00 AM
- Health and wellness drug product innovator Lexaria Bioscience has developed a patented technology — DehydraTECH (TM) — which enhances the bioavailability of fat-soluble drugs and molecules
- Lexaria continues to research DehydraTECH’s ability to improve the speed and bioavailability of cannabidiol (“CBD”) in treating high blood pressure and epileptic conditions
- The company continues its research demonstrating the ability of its technology -to enhance the performance of antiviral drugs and other active pharmaceutical ingredients
- Sublicensing DehydraTECH continues to create revenues for the company
- Lexaria has additionally pursued the use of its drug-enhancing technology, in partnership with sublicensees, for making adult-use recreational cannabis more effective
The potential for drug innovator Lexaria Bioscience’s (NASDAQ: LEXX) patented DehydraTECH(TM) technology to transform the pharmaceutical industry continues to display itself in clinical trials and licensing deals that advance use and awareness of the technology.
To view the full source article, visit: THIS LINK
|
|
Featured Event
BizCann Expo
May 21-22, 2022 - Medellin, Colombia
Whether you’re an established canna-business provider, or you are looking to get into this new exciting industry, BizCann Expo has all the resources you'll need to connect to potential canna-entrepreneurs, find services, launch your idea, or venture into a successful business. See what BizCann can do for you!
THE CANNABIS GATEWAY TO SOUTH AMERICA
Deep in the Andes mountain, the city of eternal spring is opening the floodgates of cannabis investment. With a surprisingly robust legislative framework, Medellin prepares to host an event that will bridge north & south american markets and jumpstart cannabusiness opportunities in the region.
For more information on tickets and discounts, please visit https://bizcannexpo.com/colombia/
Speakers
- Viviana Giraldo - "The Story Behind Colombiana de Cannabis and the Vision of the Future"
- Sandra Carrillo MD MHSM - "Medical Cannabis: Scientific Evidence (in Spanish or English)"
- Rodolfo Alberto Mejia Cruz - "The Tropicalization of cannabis cultivation"
- Javier Amaya - "CBD and Sports "
Upcoming Events
|
|
About CannabisNewsWire (CNW)
CannabisNewsWire (CNW) is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. Leveraging a professional team of journalists and writers, CNW introduces private and public companies to a wide audience of investors, consumers,
journalists and the general public via social media and a rapidly expanding network of over 5,000 key distribution outlets. Cutting through information overload, CNW's innovative and proprietary systems clearly and succinctly deliver its clients much needed visibility, recognition and brand awareness. CNW is where news, content and information converge.
|
